Dear Sir, Lam et al. [1] investigated the effect of cholesterol-lowering therapy with an HMG CoA reductase inhibitor (lovastatin) for 2 years on the progression of diabetic nephropathy in 34 non-insulin-dependent diabetic (NIDDM) patients. The authors conclude that effective normalization of hypercholesterolaemia may retard the progression of diabetic nephropathy. I would like to challenge this conclusion, based on the following considerations.
A heterogeneous group of NIDDM patients was investigated, 10 with microproteinuria, and 24 with macroproteinuria. No information is available on the causes of proteinuria. This is important since previous studies have demonstrated that 25-40 % of macroalbuminuric NIDDM patients suffer from non-diabetic glomerulopathies [2] [3] [4] . Proteinuric NIDDM patients with no retinopathy have a fifty-fifty chance of having diabetic or non-diabetic glomerulopathy [2] .
It is difficult to understand why the investigation was carried out as a single blind rather than a double blind study.
The authors applied intra group test rather than intergroup test for their statistical analysis. The former procedure is inappropriate since the correct statistical analysis in a parallel study is to compare the change from baseline to 2 years in the main end-point variables (glomerular filtration rate [GFR], creatinine, proteinuria) between the two groups. No power calculation is presented. The lovastatin and placebo treated groups both had a rise in proteinuria and serum creatinine while glomerular filtration rate remained unchanged in the actively treated arm and dropped in the placebo treated arm. The drop in the placebo treated arm occurred from 12 to 24 months. However, the authors state: "There was no significant difference in GFR, serum creatinine, or 24-h urinary protein excretion between the two groups at baseline, 12 months or 24 months". This intergroup analysis is more valid than the intragroup analysis mentioned above. However, the correct analysis is comparison of the changes which occurred during the trial period between the two groups.
Finally, the two original studies dealing with the effect of HMG CoA reductase inhibitor in IDDM and NIDDM patients with hypercholesterolaemia and diabetic nephropathy have been neglected [5, 6] .
The present study does not allow for a valid interpretation regarding the potential beneficial effect of cholesterol-lowering therapy due to flaws in patient material, diagnostic criteria for nephropathy, design and most important incorrect statistical analysis. Response from the authors Dear Sir, With reference to the comments from Dr. Parving regarding our study published in Diabetologia [1] , I wish to offer the following explanations.
Regarding the cause of proteinuria in our patients, 20 (59 %) had diabetic retinopathy. Among the 14 patients who had no retinopathy only 5 were hypertensive, 2 had hypertension and diabetes diagnosed at the same time and 3 had hypertension diagnosed 3-9 years after the diagnosis of diabetes, around the time of presentation of proteinuria. The other 10 had known diabetes for a mean of 5.3 years. None of the 34 patients had other known causes of parenchymal or obstructive kidney diseases. We can thus assume that the great majority of the study patients had diabetic glomerulopathy.
At any rate, a benefit of cholesterol lowering therapy on renal function has also been reported in patients with non-diabetic nephrotic syndrome [2] .
The aim of this study was to compare the effect on renal function of normalization of hypercholesterolaemia vs persistent hypercholesterolaemia, and not simply to compare the effects of lovastatin vs placebo on serum lipids and renal function. Thus the dose of lovastatin had to be increased until the target cholesterol level was achieved. There were therefore logistic difficulties in using the double-blind design. Anyway, although the physician was aware of the grouping, the control of glycaemia and hypertension was very similar between the two groups. Furthermore, the research nurse who carried out the glomerular filtration rate (GFR) studies and the laboratory technicians were not aware of the grouping of the study subjects and hence the conclusions regarding the changes in renal function could not have been affected by the study design.
We applied both intragroup and intergroup statistical tests which are both acceptable means of statistical analysis for these data. Although this study involves more patients and a much longer study period than previous studies addressing the benefit of cholesterol-lowering therapy on diabetic nephropathy [3, 4] , the patient numbers and study duration were still Letter to the editors relatively insufficient for studying the progression of a chronic pathological process, for which the rate of deterioration is highly variable between patients though quite constant for a given individual. The above factors may explain why we could not demonstrate a statistically significant difference in GFR between the two groups at 24 months, although there was a trend towards a lower mean GFR in the placebo group. In the conclusion we have already conceded that our findings were preliminary and only supportive (not confirmative) of a potential benefit of cholesterol-lowering therapy on the progression of nephropathy in these patients.
The two studies referred to by Dr. Parving [3, 4] showed no benefit of simvastatin on renal function in IDDM (12 on treatment) and NIDDM (8 on treatment) patients after 12 and 36 weeks, respectively. These negative findings can be readily explained by the small numbers of patients and short study duration as explained above.
In conclusion, we believe that our conclusions, as presented in the published manuscript, are definitely valid. We also wish to thank the many workers in this field who have expressed interest in our preliminary findings. We certainly hope that longterm, multi-centre studies involving much larger numbers of patients can be carried out to address this controversial issue which is of potential therapeutic importance.
Yours sincerely, K.S.L.Lam
